Ewing sarcoma
is the second most common bone cancer in children and
adolescents and constitutes 40%-45% of malignant bone tumors in
this group. Consecutive clinical trials have clearly established
the essential role of multidrug chemotherapy and local control
measures in curative strategies for this disease. This combined
modality approach has led to improvement in long-term
disease-free survival to about 70% in patients with localized or
non-metastatic Ewing sarcoma. Review of published data shows
that in Ewing sarcoma, local tumor control can be achieved with
either surgery or radiotherapy (RT) or a combination of both.
Furthermore, the trials have systematically assessed the
importance of sequence and timing of local therapy on outcome.
Current data recommends timing for local control to be 10-12
weeks after neo-adjuvant chemotherapy, and delay beyond 16 weeks
has been shown to negatively impact survival [1].
Choice of local control modality (surgery, surgery combined with
radiotherapy, or radiotherapy alone) and its impact on clinical
outcomes such as survival and relapse in patients with
non-metastatic Ewing sarcoma is the subject addressed by Zhu,
et al. [2] in their article in this issue of the journal. In
the absence of randomized trials that directly compare these
modalities, the authors have attempted an indirect statistical
approach using network meta-analysis to answer this question.
Ewing sarcoma is well known to be a radiosensitive tumor hence
both surgery and RT represent effective local treatment
modalities. However, recent trends for local management in Ewing
sarcoma have favored the surgical approach. This trend may be
attributed not only to availability of better surgical
techniques, but is also based on reports of increased incidence
of local failure rates with RT. These studies report three times
higher local relapses in patients treated with radiation alone
(failure rate of 30%) as compared to patients treated with
surgery alone where the rates were less than or equal to 10%
[3-6]. However, we need to interpret these results with caution,
as these studies are retrospective and non-randomized and
therefore susceptible to inherent selection bias. For example,
it has been observed that cases where complete surgical excision
was possible had better survival than those treated with RT. On
the other hand, tumors that were not amenable to surgical
excision and hence treated by radiotherapy alone were often
associated with unfavorable features like large volume, central
axis location or neurovascular involvement.
Surgery does offer certain advantages; it provides an
opportunity to assess response to neo-adjuvant chemotherapy,
reassess disease status and reduces the risk of second malignant
neoplasms associated with RT. Therefore, the increasing use of
surgery as local control modality has led to re-evaluation of
the indications for radiotherapy. It is important to remember
that surgery and RT are complimentary modalities in the
management of Ewing sarcoma, not competitive.
Radiotherapy techniques and
indications for Ewing sarcoma have evolved in the last few
decades. Definitive radiotherapy is indicated for tumors that
are considered unresectable (like sacral tumors crossing
midline) or if the morbidity associated with surgery is deemed
too high. It is generally agreed that adjuvant radiotherapy
(combination of surgery and RT) should be given to patients with
positive or very close margins, although various series have
used differing cut-offs for amounts of viable tumor in the
excised specimen. For others, there are conflicting views on
integrating radiotherapy pre-operatively and post-operatively.
Euro-Ewing-2012 radiotherapy guidelines recommend postoperative
RT in the following clinical situations: if all tissues involved
by the pre-chemotherapy tumor volume have not been surgically
excised (as often seen in pelvic and sacral sarcomas) or if the
histological response to pre-operative chemotherapy is poor
(<90% necrosis) despite presence of negative surgical margins
[7]. Other indications of postoperative RT include a displaced
pathological fracture, Askin tumor presenting with pleural
effusion and spinal/paraspinal disease where wide surgical
excision is unlikely. There are emerging data that show benefit
of pre-operative radiotherapy in certain specific clinical
situations. These include Ewing sarcoma located at sites like
the pelvis or rib, where it allows better delineation of tumor
volume and also when the volume of treatment would be smaller
than if administered post-operatively. Newer techniques like
Proton beam radiotherapy have recently been used in patients
with Ewing sarcoma. Unlike the standard photon radiotherapy,
with the use of proton beam one can minimize radiotherapy to
adjacent normal structures while maintaining full dose to the
tumor. This technique would therefore be greatly advantageous in
patients where the tumor is in close proximity to critical
structures like the eye or spinal cord, as well as for young
children receiving curative treatment; wherein it would reduce
the risk of radiation-induced second malignancy. Hence, we
observe that both surgery and radiotherapy have their relative
merits, but due to biases in patient selection the conclusions
may be obscured.
In an ideal situation, local
treatment should be individualized taking into consideration
various factors based on patient characteristics, the likely
benefit and harm of the treatment modality and preference of the
patient. The selection strategy should be planned with the goal
of optimizing local tumor control while minimizing therapy
related adverse effects.
In conclusion, these decisions about
local therapy are usually complex and should preferably be made
by a bone sarcoma or musculoskeletal multidisciplinary team that
includes surgical, radiotherapy and pediatric oncologists,
together with the family. The published study [2] adds to the
evidence-base for making informed decisions by such teams.
Competing interests:
None; Funding: None.
REFERENCES
1. Lin TA, Ludmir EB, Liao
KP, McAleer MF, Grosshans DR, McGovern SL, et al. Timing
of local therapy affects survival in Ewing sarcoma. Int J Radiat
Oncol Biol Phys. 2019;104:127–136.
2. Zhu H, Li Y, Xie X,
Zhang S, Xue Y, Fan T. Efficacy of local control strategies for
ewing sarcoma after neoadjuvant chemotherapy: A network
meta-analysis. Indian Pediatr. 2020;57:527-32.
3. Bacci G, Forni C, Longhi
A, Ferrari S, Donati D, Paolis M, et al. Long term
outcome for patients with non metastatic Ewing’s sarcoma treated
with adjuvant and neoadjuvant chemotherapies. 402 patients
treated at Rizzoli between 1972 and 1992. European J Cancer.
2004;40:73 83.
4. Donaldson SS, Torrey M,
Link MP, Glicksman A, Gilula L, Laurie F, et al. A
multidisciplinary study investigating radiotherapy in Ewing’s
sarcoma: End results of POG #8346. Int J Radiat Oncol Biol
Phys.1998;42:125 35.
5. Krasin MJ, Rodriguez
Galindo C, Billups CA, Davidoff AM, Neel MD, Merchant TE, et
al. Definitive irradiation in multidisciplinary management
of localized Ewing sarcoma family of tumors in pediatric
patients: Outcome and prognostic factors. Int J Radiat Oncol
Biol Phys. 2004;60: 830 8.
6. Schuck A, Ahrens S,
Paulussen M, Kuhlen M, Konemann S, Rube C, et al. Local
therapy in localized Ewing tumors: Results of 1058 patients
treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J
Radiat Oncol Biol Phys.2003; 55:168 77.
7. Gerrand C, Athanasou N,
Brennan B, Grimer R, Judson I, Morland B, et al. UK
guidelines for the management of bone sarcomas. Clin Sarcoma
Res. 2016; 6:7-27.